Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALLO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Anti-CD52 Monoclonal Antibody ALLO-647 | Relapsed or Refractory Large B Cell Lymphoma, Rela | Phase 1/2 · NCT04416984 | Active not recruiting |
| Fludarabine | Relapsed or Refractory Large B Cell Lymphoma, Rela | Phase 1/2 · NCT04416984 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not ALLO's own candidates): Cyclophosphamide, Nirogacestat.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALLO holds $457.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $22.5M/quarter from operations, an estimated runway of 61.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALLO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 30,146,963 | 8.73% | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | Institution (13F) | 22,446,668 | 6.50% | 2026-06-30 |
| Pfizer Inc. | Institution (13G, 5%+) | 22,032,040 | 6.38% | 2025-11-06 |
| Frazier Life Sciences Public Fund, L.P. | 5%+ holder (13G) | 19,445,046 | 5.63% | 2026-06-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 19,025,826 | 5.51% | 2026-06-30 |
| TPG GP A, LLC | Institution (13F) | 18,716,306 | 5.42% | 2026-06-30 |
| Sio Capital Management, LLC | Institution (13F) | 13,323,431 | 3.86% | 2026-06-30 |
| Primecap Management Company | Institution (13F) | 13,123,440 | 3.80% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 12,166,636 | 3.52% | 2026-06-30 |
| FMR, LLC | Institution (13F) | 12,009,043 | 3.48% | 2026-06-30 |
| Citadel Advisors Llc | Institution (13F) | 10,087,770 | 2.92% | 2026-06-30 |
| David D Chang President and CEO, Director · +1.78M options |
Insider | 6,351,707 | 1.84% | 2026-03-16 |
Share count 345,490,881 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-21 filed 2026-08-25 |
Douglas Earl Martin |
Sale (S) | 29,697 | $2.12 | 488,267 |
| 2026-07-01 filed 2026-07-06 |
Roberts Zachary |
Option award (A) | 476,190 | – | – |
| 2026-07-01 filed 2026-07-06 |
Roberts Zachary |
Option award (A) | 134,530 | – | – |
| 2026-06-18 filed 2026-06-23 |
Barrett Elizabeth A. |
Option award (A) | 95,400 | – | – |
| 2026-06-18 filed 2026-06-23 |
MESSEMER DEBORAH M. |
Option award (A) | 95,400 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALLO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →